NOV 19, 2019 8:21 PM PST

Experimental Cholesterol-Lowering Drug

WRITTEN BY: Nouran Amin

A recent study shows that patients who take a maximum dose of statin drugs in addition to a twice-yearly injection of the experimental cholesterol-lowering drug, inclisiran, was effective at reducing low-density lipoprotein (LDL) cholesterol, often called bad cholesterol. Results of the study were generated from the ORION-10, a phase 3 placebo-controlled, double-blind, randomized clinical trial.

Learn more about LDL cholesterol:

 

 

When increased levels of LDL cholesterol builds up in the walls of the arteries, blood cannot pass through efficiently which leads to blockage. This blockage, as a result of hard and narrow capillaries, puts a patient at risk of heart attacks and strokes. "Maintaining low LDL over a sustained period is essential to reduce the risk of heart attacks and stroke," says R. Scott Wright, M.D., a Mayo Clinic cardiologist and principal investigator of ORION-10 trial.

Inclisiran is the only siRNA drug that works to lower cholesterol. Developed by the Medicines Company, the drug works to mimic a gene variant and prevent the production of the protein PCSK9, this in turn lowers LDL.

"The data show that inclisiran dosed twice-yearly achieved durable and potent LDL reductions with an excellent safety profile, and no treatment-related liver or kidney side effects," Dr. Wright says. "Twice-yearly administration by a health care professional coincides with typical patient visits, which can help with medication adherence."

Source: Science Daily

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
MAR 09, 2021
Drug Discovery & Development
Personalized Psychedelic Assisted-Therapy
MAR 09, 2021
Personalized Psychedelic Assisted-Therapy
Psychedelics have long been known for their therapeutic in treating mental health disorders. However, there remains a co ...
MAR 24, 2021
Drug Discovery & Development
Three Compounds May Be Suitable for SARS-CoV-2
MAR 24, 2021
Three Compounds May Be Suitable for SARS-CoV-2
Researchers have found that that three common antiviral and antimalarial therapeutics may be effective in vitro at targe ...
APR 12, 2021
Drug Discovery & Development
Epidural Use Not Linked To Autism
APR 12, 2021
Epidural Use Not Linked To Autism
Epidurals are a form of pain relief during childbirth and is used by more than half of all women in labor. Many women wh ...
MAY 03, 2021
Drug Discovery & Development
Low Dose Radiation May Improve Symptoms of Alzheimer's
MAY 03, 2021
Low Dose Radiation May Improve Symptoms of Alzheimer's
While high doses of radiation are known to be harmful, low doses may be able to help the body protect and repair. And no ...
MAY 15, 2021
Neuroscience
Eye Scans May Indicate Early Signs of Alzheimer's
MAY 15, 2021
Eye Scans May Indicate Early Signs of Alzheimer's
Researchers from the University of California San Francisco have found that retinal scans can detect changes in blood ve ...
JUN 11, 2021
Drug Discovery & Development
Laughing Gas Shows Promise in Rapid Relief of Treatment-Resistant Depression
JUN 11, 2021
Laughing Gas Shows Promise in Rapid Relief of Treatment-Resistant Depression
Researchers led by the University of Chicago Medicine and Washington University have found that low doses of laughing ga ...
Loading Comments...